Related Experiment Video
Updated: Dec 24, 2025
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer
Vida Vafaizadeh1, Zeinab Barekati1
1Department of Biomedicine, University of Basel, Basel, Switzerland.
Abstract:
The immune checkpoint blockade therapy has drastically advanced treatment of different types of cancer over the past few years. Female breast cancer is the second leading cause of death in the overall burden of cancers worldwide that is encouraging healthcare professionals to improve cancer care management. The checkpoint blockade therapies combined with novel agents become the recent focus of various clinical trials in breast cancer. However, identification of the patients who are responsive to these therapeutic strategies remained as a major issue for enhancing the efficacy of these treatments. This highlights the unmet need in discovery and development of novel biomarkers to add predictive values for prosperous personalized medicine. In this review we summarize the advances done in the era of biomarker studies and highlight their link in supporting breast cancer immunotherapy.
Insights
Immune checkpoint blockade therapy shows promise for breast cancer. Identifying responsive patients through novel biomarkers is crucial for effective personalized medicine and improved immunotherapy outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Biomarker Discovery
Background:
- Immune checkpoint blockade therapy has significantly advanced cancer treatment.
- Female breast cancer remains a leading cause of cancer death globally.
- Improving breast cancer care management is a key healthcare priority.
Purpose of the Study:
- To review advances in biomarker studies for breast cancer immunotherapy.
- To highlight the role of biomarkers in predicting treatment response.
- To address the need for novel predictive biomarkers in personalized medicine.
Main Methods:
- Literature review of recent biomarker studies in breast cancer immunotherapy.
- Analysis of clinical trials combining checkpoint blockade with novel agents.
- Synthesis of current knowledge on predictive biomarkers for immunotherapy.
Main Results:
- Biomarker research is essential for identifying patients who benefit from immunotherapy.
- Novel biomarkers are needed to enhance the efficacy of current treatments.
- Personalized medicine approaches require robust predictive biomarker strategies.
Conclusions:
- Biomarker discovery is critical for the success of breast cancer immunotherapy.
- Predictive biomarkers will enable more effective personalized treatment strategies.
- Further research into biomarkers will improve patient outcomes in breast cancer.
Related Concept Videos
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:18Cancer